Literature DB >> 27117107

[Influenza surveillance].

Karolina Bednarska1, Ewelina Hallmann-Szelińska1, Katarzyna Kondratiuk1, Lidia B Brydak1.   

Abstract

Influenza surveillance was established in 1947. From this moment WHO (World Health Organization) has been coordinating international cooperation, with a goal of monitoring influenza virus activity, effective diagnostic of the circulating viruses and informing society about epidemics or pandemics, as well as about emergence of new subtypes of influenza virus type A. Influenza surveillance is an important task, because it enables people to prepare themselves for battle with the virus that is constantly mutating, what leads to circulation of new and often more virulent strains of influenza in human population. As vaccination is the most effective method of fighting the virus, one of the major tasks of GISRS is developing an optimal antigenic composition of the vaccine for the current epidemic season. European Influenza Surveillance Network (EISN) has also developed over the years. EISN is running integrated epidemiological and virological influenza surveillance, to provide appropriate data to public health experts in member countries, to enable them undertaking relevant activities based on the current information about influenza activity. In close cooperation with GISRS and EISN are National Influenza Centres--national institutions designated by the Ministry of Health in each country.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27117107     DOI: 10.5604/17322693.1199709

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  2 in total

1.  The Sentinel System as the Main Influenza Surveillance Tool.

Authors:  K Cieślak; D Kowalczyk; K Szymański; L B Brydak
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

2.  Evaluation of the 2017/18 Influenza Epidemic Season in Poland Based on the SENTINEL Surveillance System.

Authors:  K Łuniewska; K Szymański; E Hallmann-Szelińska; D Kowalczyk; R Sałamatin; A Masny; L B Brydak
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.